Bio Techne Corp (TECH) Earnings Misses Estimates Despite Increment in Net Sales – A Detailed Analysis

Bio Techne Corp on Smartkarma

Baptista Research, an independent analyst on Smartkarma, recently published two research reports on Bio Techne Corp. The first report, titled ‘Bio-Techne Corporation: The Lunaphore Acquisition & Enhanced Spatial Biology Capabilities! – Major Drivers‘, praised the company’s 5% organic growth in the last quarter, despite the challenges of reduced biotech funding in North America. The report also discussed the positive growth trajectory of the company in Europe, and how its cell and gene therapy business grew over 20% for the fiscal year.

The second report, ‘Bio-Techne Corporation: Collaboration With Lunaphore & Other Drivers‘, discussed the company’s weak quarter with revenues below market expectations. It highlighted the key drivers of physician uptake, utilization of its ExoDx prostate test, and increased demand for its cell therapy workflow solutions. The report also mentioned the Exosome Diagnostics business, which was strong in the quarter due to better marketing, a stronger commercial team, and a modified Medicare LCD.

A look at Bio Techne Corp Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Bio-Techne Corp is a promising biotechnology company that specializes in proteins, cytokines, growth factors, immunoassays and small molecules. Its long-term outlook is positive, as indicated by its Smartkarma Smart Scores. The company scores well on factors such as growth, resilience and momentum, while its value and dividend scores are lower. Despite this, the company is well-positioned to continue developing and manufacturing biotechnology products and clinical diagnostic controls.

The company has a long-term outlook that is bolstered by its strong growth, resilience and momentum scores. The company is expected to continue developing and manufacturing biotechnology products and clinical diagnostic controls, ensuring its long-term success. As the company continues to innovate and grow, its value and dividend scores are expected to improve, furthering the company’s long-term outlook.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

Before it’s here, it’s on Smartkarma